Afuco™ Anti-IL23A ADCC Therapeutic Antibody (Brazikumab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL23A. Brazikumab is a human monoclonal antibody that can be potentially used in the treatment of Crohn's disease (CD).
Supplier Creative Biolabs
Product # AFC-TAB-008ML
Pricing Inquiry
Host Human
Target IL23A
Species Reactivity Human
Type ADCC enhanced antibody
Applications ELISA, IHC, FC, IP, IF, Inhib
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback